Quantum-Si (QSI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 Apr, 2026Executive summary
The annual meeting will be held virtually on May 15, 2026, with voting and Q&A available online.
Stockholders will vote on electing ten directors, ratifying the auditor, and approving executive compensation.
Voting rights are based on share class, with Class B shares carrying 20 votes per share.
Proxy materials are primarily distributed electronically to conserve resources and reduce costs.
Voting matters and shareholder proposals
Proposals include electing ten directors, ratifying PricewaterhouseCoopers LLP as auditor, and a non-binding say-on-pay vote.
Board recommends voting in favor of all proposals.
Majority vote is required for each proposal; abstentions and broker non-votes have no effect.
Stockholders can submit proposals for the 2027 meeting by December 2, 2026.
Board of directors and corporate governance
Board consists of ten members, eight of whom are independent under Nasdaq rules.
Board committees include audit, compensation, and nominating/governance, all with independent directors.
The company qualifies as a "controlled company" due to majority voting power held by Dr. Rothberg but maintains a majority independent board.
Corporate governance guidelines and an insider trading policy are in place.
Latest events from Quantum-Si
- Annual meeting to elect directors, ratify auditor, and approve executive pay, with board support.QSI
Proxy filing1 Apr 2026 - 2026 emphasizes consumables growth and Proteus launch, with strong cash reserves and cost control.QSI
Q4 20253 Mar 2026 - Q2 2024 revenue rose 203% to $622,000, with a 57% margin and cash runway into 2026.QSI
Q2 20242 Feb 2026 - Rapid innovation and commercial expansion position the platform for strong growth in proteomics.QSI
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Automated protein sequencing platform drives adoption and innovation across research sectors.QSI
H.C. Wainwright 26th Annual Global Investment Conference21 Jan 2026 - Q3 revenue up 252.9% to $787,000, but full-year guidance was lowered amid longer sales cycles.QSI
Q3 202414 Jan 2026 - Proteus and Platinum Pro launch drive scalable, automated, and versatile proteomics workflows.QSI
Investor Day 202413 Jan 2026 - Q4 revenue up 52% sequentially, 183% YoY, $86M raised, and cash runway into 2027.QSI
Q4 202424 Dec 2025 - Up to $300M in securities may be offered, with $100M via at-the-market sales through Leerink Partners.QSI
Registration Filing16 Dec 2025